In the United Kingdom, after arduous analysis and meticulous evaluation of evidence-based data, The National Institute for Clinical Efficiency recommended in their practice guidelines MRI/US Fusion Prostate Biopsies as the preferred method for identifying prostate cancer given its clinical efficiency cost effective profile
Over the last 2-3 years several scientific studies have evaluated the impact in diagnostic precision that is provided by MRI/US Fusion Biopsies. However, none has been as thorough and telling as the recently reported investigation from the national Institutes of Health in the United States. The investigators in this study lead by Dr. Peter Pinto - published on JAMA in 2015 - evaluated 1,003 men referred for a prostate biopsy. Using a crossover model all patients underwent both a "traditional" TRUS Bx and a MRI/US Fusion Prostate Biopsy. The results were clear, an increased yield of 30% in detecting clnically significant and aggressive prostate cancer tumors associated to the MRI/US Fusion Technique